

Elena Raschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8774793/publications.pdf>

Version: 2024-02-01

63
papers

4,136
citations

126901

33
h-index

189881

50
g-index

65
all docs

65
docs citations

65
times ranked

2880
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. <i>Nature Reviews Rheumatology</i> , 2011, 7, 330-339.	8.0	482
2	Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered Î²2-glycoprotein I. <i>Arthritis and Rheumatism</i> , 2000, 43, 140-150.	6.7	290
3	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. <i>Blood</i> , 2003, 101, 3495-3500.	1.4	290
4	Statins prevent endothelial cell activation induced by antiphospholipid (anti-Î²2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. <i>Arthritis and Rheumatism</i> , 2001, 44, 2870-2878.	6.7	250
5	Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 236-250.	2.7	205
6	Infectious origin of the antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 2-6.	0.9	203
7	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1327-1333.	0.9	184
8	Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. <i>American Journal of Kidney Diseases</i> , 2001, 37, 490-498.	1.9	168
9	Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome. <i>Journal of Autoimmunity</i> , 2000, 15, 237-240.	6.5	139
10	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1602-1613.	6.7	137
11	Endothelium and the brain in CNS lupus. <i>Lupus</i> , 2003, 12, 919-928.	1.6	102
12	Pathogenic role of anti-Î²2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of Î²2-glycoprotein I binding to trophoblast cells and functional effects of anti-Î²2-glycoprotein I antibodies in vitro. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 462-467.	0.9	97
13	Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. <i>Journal of Immunology</i> , 1998, 160, 5572-8.	0.8	94
14	Endothelial cell activation by antiphospholipid antibodies. <i>Clinical Immunology</i> , 2004, 112, 169-174.	3.2	91
15	Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. <i>Lupus</i> , 1999, 8, 423-429.	1.6	85
16	Interleukinâ€17A+ Cell Counts Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated With the Extent of Skin Involvement. <i>Arthritis and Rheumatism</i> , 2013, 65, 1347-1356.	6.7	85
17	Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. <i>Arthritis Research and Therapy</i> , 2013, 15, R151.	3.5	74
18	Inflammatory response and the endothelium. <i>Thrombosis Research</i> , 2004, 114, 329-334.	1.7	68

#	ARTICLE	IF	CITATIONS
19	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. <i>Lupus</i> , 2008, 17, 938-943.	1.6	63
20	Î²2-Glycoprotein I as a "Cofactor"™ for anti-phospholipid reactivity with endothelial cells. <i>Lupus</i> , 1998, 7, 44-47.	1.6	54
21	Î²2-glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , 2014, 55, 42-50.	6.5	52
22	Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. <i>Arthritis and Rheumatism</i> , 2010, 62, 1504-1512.	6.7	51
23	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2004, 3, 510-515.	5.8	50
24	Humoral autoimmunity against endothelium: theory or reality?. <i>Trends in Immunology</i> , 2005, 26, 275-281.	6.8	50
25	Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Anti-Î²2 Glycoprotein I Antibodies. <i>American Journal of Reproductive Immunology</i> , 1997, 38, 212-217.	1.2	49
26	ANTIPHOSPHOLIPID ANTIBODIES AND THE ENDOTHELIUM. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 587-602.	1.9	49
27	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. <i>International Immunology</i> , 2001, 13, 349-357.	4.0	45
28	Endothelium as a target for antiphospholipid antibodies. <i>Immunobiology</i> , 2003, 207, 29-36.	1.9	45
29	Obstetric and vascular APS: Same autoantibodies but different diseases?. <i>Lupus</i> , 2012, 21, 708-710.	1.6	41
30	Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. <i>Arthritis and Rheumatism</i> , 2002, 46, 1595-1601.	6.7	40
31	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	3.5	40
32	Updating on the Pathogenic Mechanisms of the Antiphospholipid Antibodies-Associated Pregnancy Loss. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 332-337.	6.5	38
33	Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2015, 27, 476-482.	4.3	35
34	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018, 20, 187.	3.5	33
35	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 265.	3.5	33
36	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016, 9, 389-400.	2.2	31

#	ARTICLE	IF	CITATIONS
37	Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. <i>Clinical and Experimental Immunology</i> , 1997, 110, 479-484.	2.6	29
38	Anti-Beta-2 Glycoprotein I Antibodies Affect Bcl-2 and Bax Trophoblast Expression without Evidence of Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 364-376.	3.8	28
39	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. <i>Journal of Autoimmunity</i> , 2009, 32, 60-63.	6.5	28
40	Anti-endothelial cell antibodies in patients with coronary atherosclerosis. <i>Immunology Letters</i> , 2000, 73, 23-27.	2.5	26
41	Transforming growth factor β 1 in the pathogenesis of autoimmune congenital complete heart block: Lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006, 54, 356-359.	6.7	25
42	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. <i>Transplantation</i> , 2008, 86, 1445-1451.	1.0	24
43	Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis. <i>Clinical and Experimental Immunology</i> , 2002, 128, 187-194.	2.6	23
44	Role of anti- β 2 glycoprotein I antibodies in antiphospholipid syndrome glycoprotein I antibodies in antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 67-73.	6.5	23
45	Toll-like receptor 4 and β 2 glycoprotein I interaction on endothelial cells. <i>Lupus</i> , 2014, 23, 1302-1304.	1.6	23
46	Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. <i>Autoimmunity Reviews</i> , 2002, 1, 55-60.	5.8	19
47	Endothelium activation in the anti-phospholipid syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2003, 57, 282-286.	5.6	18
48	Antiendothelial Cell Antibodies (AECA): From a Laboratory Curiosity to Another Useful Autoantibody. , 1999, , 285-294.		8
49	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. <i>Open Rheumatology Journal</i> , 2018, 12, 248-260.	0.2	5
50	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES. , 2007, , 725-731.		4
51	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 55-67.	0.1	4
52	Functional Heterogeneity of Pathogenic Anti-Endothelial Cell Antibodies. , 2001, , 211-220.		2
53	Mechanisms of Action of the Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 31-46.	0.1	1
54	Antiphospholipid/Endothelial Cell Interaction in the Pathogenesis of the Antiphospholipid Syndrome. , 2002, , 79-89.		1

#	ARTICLE	IF	CITATIONS
55	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?. , 2012, , 79-101.		1
56	What are the Target Cells and Receptors that are Recognized by Antiphospholipid Antibodies?. , 2012, , 103-113.		1
57	The Story of the Murine Antiendothelial Monoclonal Antibody BGM : From Patients' Bedside to Laboratory Bench and From Animal Models to Patients. Clinical Reviews in Allergy and Immunology, 2000, 18, 3-10.	6.5	0
58	OP0060â€¦Beta2GPI and TLR4 interaction on endothelial cells: A bridge between innate and adaptive immunity in APS. Annals of the Rheumatic Diseases, 2013, 71, 73.2-73.	0.9	0
59	A3.5â€¦Toll like receptors: a crossroad in scleroderma etiopathogenesis. Annals of the Rheumatic Diseases, 2014, 73, A43.2-A44.	0.9	0
60	Antiendothelial Cell Antibodies. , 2014, , 723-729.		0
61	OP0285â€¦The Pathogenic Role of Immune Complexes Containing Scleroderma-Specific Autoantibodies in the Inductor Phase of the Disease. Annals of the Rheumatic Diseases, 2015, 74, 180.2-180.	0.9	0
62	AB0201â€¦THE PATHOGENIC EFFECTS OF IMMUNE COMPLEXES CONTAINING SCLERODERMA-SPECIFIC AUTOANTIBODIES IN ENDOTHELIAL CELLS. , 2019, , .		0
63	Role of anti-Î²2 glycoprotein I antibodies in antiphospholipid syndromeglycoprotein I antibodies in antiphospholipid syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 67-73.	6.5	0